Latest researches of USA National Cancer Institute show, that Metformin , which is a mainstay of treatment for patients with type 2 diabetes may inhibit tumor growth as well and use for lung cancer prevention. This diabetes drug was able to prevent tobacco-carcinogen induced lung tumors.
For the current study, treated mice with metformin for 13 weeks following exposure to a nicotine-derived nitrosamine (NNK), which is the most prevalent carcinogen in tobacco and a known promoter of lung tumorigenesis.
When given orally, metformin was well tolerated and reduced tumor burden by 40 percent to 50 percent. Levels of metformin reached in mice are readily achievable in humans.
Further evaluated the effects of metformin on a series of biomarkers for lung tumorigenesis and found that it inhibited mammalian target of rapamycin (mTOR), which promotes lung tumor growth, by decreasing levels of circulating insulin and IGF-1. This effect was even more profound when metformin was administered to mice by injection, which reduced lung tumor burden by 72 percent.